tirzepatide tiene efecto rebote después de la tirzepatida: ¿siempre ocurre? La OCU denuncia «efecto rebote»

Patients taking semaglutide GLP-1 must be closely monitored by their medical provider for any potential side effects such as nausea, diarrhea, or hypoglycemia

A functional duo designed to support those with a conscious and active lifestyle

Advocating for integrated care, for a treatment plan that accounts for your mental health alongside your physical health, is not asking for too much

No auto-refills without follow-up

Tirzepatide tends to cause slightly less nausea than semaglutide at equivalent efficacy levels, which is one reason some patients prefer it

Clinical trials show 15-22% total body weight loss with tirzepatide and 12-17% with semaglutide over 72 weeks